Tech Company Financing Transactions

Caris Life Sciences Funding Round

Caris Life Sciences, operating out of Irving, secured $310 million from Coatue Management, Highland Capital Partners and ClearBridge Investments.

Transaction Overview

Company Name
Caris Life Sciences
Announced On
10/28/2020
Transaction Type
Debt
Venture Equity
Amount
$310,000,000
Round
Undisclosed
Investors

Coatue Management (Lead Investor)

Highland Capital Partners (Lead Investor)

ClearBridge Investments

First Light Asset Management

Millennium Management

Neuberger Berman Private Equity Funds

OrbiMed

Sixth Street Partners (Vijay Mohan)

T. Rowe Price

Proceeds Purpose
Caris will dedicate the new capital to fund its continued growth in precision medicine to reinvent cancer care, accelerate innovative product development and pursue new initiatives in both the clinical trial and biopharmaceutical markets.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
750 West John Carpenter Freeway 800
Irving, TX 75039
USA
Phone
(888) 979-8669
Website
www.carislifesciences.com
Email Address
[email protected]
Overview
Caris Life Sciences was founded with a very simple but powerful purpose -- to help improve the lives of as many people as possible. With transformative technologies, we are revolutionizing precision medicine to provide physicians and patients with the highest quality information about their health.
Profile
Caris Life Sciences LinkedIn Company Profile
Social Media
Caris Life Sciences Company Twitter Account
Company News
Caris Life Sciences News
Facebook
Caris Life Sciences on Facebook
YouTube
Caris Life Sciences on YouTube

Management Team

Title
Name
Email & Social
Chairman
Brian Brille
  Brian Brille LinkedIn Profile  Brian Brille Twitter Account  Brian Brille News  Brian Brille on Facebook
Chief Executive Officer
David Halbert
  David Halbert LinkedIn Profile  David Halbert Twitter Account  David Halbert News  David Halbert on Facebook
Chief Financial Officer
Thomas Parker
  Thomas Parker LinkedIn Profile  Thomas Parker Twitter Account  Thomas Parker News  Thomas Parker on Facebook
Chief Information Officer
Ron Merlino
  Ron Merlino LinkedIn Profile  Ron Merlino Twitter Account  Ron Merlino News  Ron Merlino on Facebook
Chief Medical Officer
Michael Korn
  Michael Korn LinkedIn Profile  Michael Korn Twitter Account  Michael Korn News  Michael Korn on Facebook
Chief Medical Officer
Matthew Oberley
  Matthew Oberley LinkedIn Profile  Matthew Oberley Twitter Account  Matthew Oberley News  Matthew Oberley on Facebook
Chief Scientific Officer
David Spetzler
  David Spetzler LinkedIn Profile  David Spetzler Twitter Account  David Spetzler News  David Spetzler on Facebook
Executive Vice President
Stephanie Thomas
  Stephanie Thomas LinkedIn Profile  Stephanie Thomas Twitter Account  Stephanie Thomas News  Stephanie Thomas on Facebook
Vice President
James Abraham
  James Abraham LinkedIn Profile  James Abraham Twitter Account  James Abraham News  James Abraham on Facebook
VP - Bus. Development
Brian Lamon
  Brian Lamon LinkedIn Profile  Brian Lamon Twitter Account  Brian Lamon News  Brian Lamon on Facebook
VP - Bus. Development
Michael Sullivan
  Michael Sullivan LinkedIn Profile  Michael Sullivan Twitter Account  Michael Sullivan News  Michael Sullivan on Facebook
VP - General Counsel
Ginger Appleberry
  Ginger Appleberry LinkedIn Profile  Ginger Appleberry Twitter Account  Ginger Appleberry News  Ginger Appleberry on Facebook
VP - General Counsel
Russ Farr
  Russ Farr LinkedIn Profile  Russ Farr Twitter Account  Russ Farr News  Russ Farr on Facebook
VP - Human Resources
Michael Halbert
  Michael Halbert LinkedIn Profile  Michael Halbert Twitter Account  Michael Halbert News  Michael Halbert on Facebook
VP - R & D
Jon Harmon
  Jon Harmon LinkedIn Profile  Jon Harmon Twitter Account  Jon Harmon News  Jon Harmon on Facebook
VP - R & D
Mark Miglarese
  Mark Miglarese LinkedIn Profile  Mark Miglarese Twitter Account  Mark Miglarese News  Mark Miglarese on Facebook

 

 

Browse more venture capital transactions:

Prev: 10/27/2020: Scorpion Therapeutics venture capital transaction
Next: 10/28/2020: Skan venture capital transaction

 

Share this article

 

Where The Data Comes From

We do our best to report on tech company VC transactions. VC investment data records reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.